glp 1 agonist parkinson Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease | Journal of Biomedical Science Current Insights, Advantages and Challenges

Phase 1: Weeks 13 (Disc Repair Priority) BPC-157: 500mcg/day subQ TB-500: 2.5mg/week subQ GHK-Cu: 1mg/day subQ Focus: disc tissue repair, nerve decompression, anti-inflammation Activity: physical therapy, gentle mobility, no loading Phase 2: Weeks 48 (Add Recomp Layer) Continue Phase 1 stack Add CJC-1295 no DAC + Ipamorelin: 100mcg each, pre-bed This layer drives GH pulsatility for tissue remodeling and begins the body recomposition phase Activity: begin light lifting as cleared by PT Phase 3: Weeks 9+ (Maintenance and Fat Loss) TB-500: Drop to maintenance 1.25mg/week BPC-157: Can drop to 250mcg/day or 5 days/week CJC+Ipa: Continue pre-bed Optional add: Tesamorelin (12mg/day, 5 days/week) for visceral fat and GH optimization pairs well with CJC+Ipa Optional add: Retatrutide for more aggressive fat loss if that's a priority What to Expect: Recovery Timeline Weeks 12: Reduced acute nerve pain is often the first noticeable change

If you are exploring ways to support overall wellness through nutrition, Immunocal may be worth learning more about as part of a balanced diet and healthy lifestyle

Easily measurable without guesswork

In this form, it can directly neutralize free radicals and support your body's detoxification processes

For example, they can increase collagen production by transporting magnesium and copper to the skin